Combination treatment for chronic Graft-versus-Host Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a combination treatment using Axatilimab and Extracorporeal Photopheresis (ECP) for patients suffering from chronic Graft-versus-Host Disease (cGVHD). Participants must have undergone allogeneic hematopoietic cell transplantation and have experienced inadequate responses to at least two prior lines of therapy. The study aims to determine if this novel combination can improve patient outcomes in managing cGVHD symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Recipient of allogeneic hematopoietic cell transplantation (HCT).
2. Age greater or equal to 12.
3. Chronic GVHD per 2014 National Institutes of Health Consensus Criteria (NCC) (Jagasia et al. 2015) or overlap syndrome requiring new therapy in patients with at least 2 prior lines of therapy, steroid refractoriness, or steroid dependence:

   1. Prior systemic lines of therapy may include corticosteroids, calcineurin inhibitor (CNI) or sirolimus, or other systemic immunosuppressive agent such as ruxolitinib, belumosudil, or ibrutinib. GVHD prophylaxis does not count as a prior line of therapy.
   2. Steroid refractory is defined as any of the following criteria:

      * i. Manifestations progress despite the use of ≥ 1 mg/kg/day prednisone for at least 1 week
      * ii. Manifestations persist without improvement despite treatment with ≥ 0.5 mg/kg/day or 1 mg/kg every other day for at least four weeks.
      * iii. Recurrence after a CR, or
      * iv. Progression after a PR.
   3. Steroid dependence is defined as inability to control cGVHD symptoms while tapering prednisone below 0.25 mg/kg/day on at least two occasions separated by at least 8 weeks. There must be evidence of clinically active cGVHD.
4. For patients receiving approved or commonly used agents, all GVHD systemic treatments should be discontinued except for corticosteroids and drugs being continued from GVHD prophylaxis at screening.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-3 as assessed at Screening.
6. Platelet count \> 50,000 platelets/μL and absolute neutrophil count \> 1,000 cells/μL as measured at Screening.
7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN), unless attributed to presumed cGVHD as measured at Screening.
8. Stable dose of corticosteroids for at least 14 days prior to treatment.
9. Sexually mature individuals must use contraception as described in Section 4.12. For individuals less than 18 years of age, sexual maturity will be determined as per treating pediatrician.

Exclusion Criteria:

1. Pregnancy or breast-feeding.
2. Active relapse of underlying malignancy.
3. History or the presence of interstitial pneumonitis or drug-related pneumonitis.
4. Active gastrointestinal (GI) bleeding.
5. Inability to tolerate volume shifts associated with ECP (e.g., inadequate renal, hepatic, pulmonary and cardiac function (ejection fraction (EF) \< 40%) per Investigator discretion.
6. History of myositis.
7. History of splenectomy.
8. History of pancreatitis.
9. History of other malignancy (within 3 years of Screening) unless treated with curative intent and approved by Principal Investigator (PI).
10. Significant, uncontrolled, or active comorbid conditions or are unable to adhere to the study requirements.
11. Acquired Immune Deficiency Syndrome (AIDS) or active hepatitis B (Hep B) or active hepatitis C (Hep C) infection.
12. Prior colony-stimulating factor-1 (CSF-1R) targeted therapies.
13. Prior history of ECP treatment failure or intolerance.
14. Intolerance to methoxsalen, heparin, or citrate products.
15. Patients with aphakia due to risk of increased retinal damage or photosensitive disease (albinism, systemic lupus erythematosus, porphyria).
16. Lack of stable IV access. Acceptable forms include central venous catheter, peripherally inserted central catheter (PICC), or peripheral IV line per institutional guidelines.
17. Insurance denial of coverage for the ECP procedure.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Ann & Robert H. Lurie Children's Hospital of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Trent P Wang, DO — University of Miami
• Study coordinator: Trent P Wang, DO
• Email: trentwang@med.miami.edu
• Phone: +1 (305) 2436444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Axatilimab versus best available therapy for children with chronic graft-versus-host disease after two or more prior treatments

  This trial will test axatilimab against the best available treatments in children aged 2–17 whose chronic graft-versus-host disease has not responded to at least two prior systemic therapies.

  Recruiting at 34 sites Phase 2 Incyte Corporation · Duarte, California and 40 other locations · NCT07124078

• Axatilimab to treat skin thickening (sclerosis) from chronic graft‑versus‑host disease

  This trial tests whether axatilimab can improve or stop worsening skin thickening (sclerosis) in adults with chronic graft‑versus‑host disease after a donor stem cell transplant.

  Recruiting at 2 sites Phase 2 Fred Hutchinson Cancer Center · Tampa, Florida and 2 other locations · NCT07011810

• Evaluating axatilimab and corticosteroids for treating chronic graft-versus-host disease

  This study is testing if adding a new drug called axatilimab to standard steroids can help people aged 12 and older who have recently developed moderate to severe chronic graft-versus-host disease feel better.

  Recruiting at 131 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 130 other locations · NCT06585774

• Axatilimab at Three Doses for Chronic GVHD

  This study tests three dose levels of axatilimab in people 2 years and older whose chronic graft-versus-host disease has not responded to at least two prior treatments.

  Recruiting at 13 sites Phase 2 Syndax Pharmaceuticals · Birmingham, Alabama and 120 other locations · NCT04710576

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• Belumosudil vs Best Available Therapy for chronic graft-versus-host disease

  In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.

  Recruiting at 3 sites Phase 3 Sanofi · Amsterdam and 2 other locations · NCT07771439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.